Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 31;8(2):453–467. doi: 10.1182/bloodadvances.2023011287

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 7. — Tumor burden stabilization/regression and late conversion to CR with repeated dosing of durvalumab after JCAR014. (A) Spider plot of the change in the sum of the product of the perpendicular diameters of ≤6 target measurable nodes and extranodal sites (SPD) over time compared with the baseline prelymphodepletion according to best response at 3 months. ∗ represents patients with extranodal disease and no measurable target lesion. ‡ represents patients who converted to CR at 1 year. PET/CT (B) and immunohistochemistry (C) images at different timepoints in a patient with late conversion to CR with continued durvalumab despite evidence of CD19^– escape. Images were taken at original magnification ×40.